A strain-release-driven, cation-templated intramolecular nucleophilic addition of tethered alkoxides to prochiral cyclopropenes is described. Employment of chiral β-and γ-amino alkoxides allowed for highly diastereoselective assembly of a small series of enantiopure cyclopropane-fused oxazepanones. It was shown that the chiral center at C-4 plays a crucial role in controlling desymmetrization of the cyclopropenyl moiety, instigated by a profound potassiumtemplated effect. The preliminary biological activities of the new cyclopropane-fused medium heterocycles against Gram-positive bacteria, Gram-negative bacteria, mycobacteria, cancer cells, and fungus were evaluated.
INTRODUCTION
Advances in base-assisted additions of heteroatom-based nucleophiles to cyclopropenes made available novel stereo-defined cyclopropyl scaffolds, 1 possessing oxygen, 2 nitrogen, 3 sulfur, 4 or halogen 5 entities, that complement transition-metal-catalyzed cyclopropanation methodologies. 6, 7 Both intermolecular (Scheme 1, eq 1) and intramolecular (Scheme 1, eq 2) addition of tethered nucleophiles, employing carbon-8 or oxygen-based species, has been reported. 9, 10 In all these studies achiral tethered nucleophilic entities were used for cyclizations affording racemic products. A diastereoselective 8-endo-trig cycloaddition using chiral cyclopropene precursor 8 has been demonstrated (Scheme 1, eq 3), 10 while a complementary approach involving intramolecular nucleophilic addition of tethered chiral alkoxides to prochiral cyclopropene moieties has not been fully explored. To date, only two examples were communicated by our group, 11 using cyclopropene 11 generated in situ via 1,2-elimination of bromocyclopropane 10 (Scheme 2). The limited availability of chiral precursors 10 warranted further studies to adapt this methodology to more stable, isolable cyclopropenes accessible via the metal-catalyzed cyclopropenation reactions. 12 Herein, we report the development of a synthetic approach that allows for modular assembly of chiral medium-sized heterocycles 6 and 12 bearing a fused cyclopropane moiety. It should be pointed out that fused oxazepines are a very important class of biologically active molecules that display diverse pharmacological activities. 1 Known bioactivities for this class of compounds include anticonvulsant, antimicrobial, anticancer, and antipsychotic agents and calcium antagonists and neuroprotectors. Development of new approaches to these important molecules, especially stereoselective, can lead to the discovery of new privilege medicinal structures. Preliminary biological studies of our new scaffolds revealed several hits showing promising antimicrobial activity against Mycobacterium abscessus, 13 a rapid-growing highly virulent chemotherapy-resistant mycobacterial pathogen.
RESULTS AND DISCUSSION
We have recently communicated an efficient synthesis of medium cyclic ethers 6 via a formal nucleophilic cyclization of bromocyclopropanes 4 (Scheme 1, eq 2), 9a involving an in situ base-assisted generation of reactive cyclopropene 5, which, once formed, is immediately trapped by a tethered alkoxide. Our computational studies suggested that the mechanism of this strain-release-driven reaction involves a transition state where the potassium ion is coordinated to both alkoxide and amide oxygens, as well as to the carbon atom bearing a partial negative charge (C-8) (TS1 in Scheme 6) . It was expected and confirmed experimentally that the templating effect induced constraints on the rotors in the tether, making the cyclization pathway more favorable vis-a-vis oligo-and polymerization. Furthermore, the rigidity of such activated complexes allowed for high diastereoselectivity of the newly formed stereogenic centers when chiral amino alcohol-tethered prochiral cyclopropenes are used as substrates. In our preliminary communication, 11 we have demonstrated two examples of such cyclization of bromocyclopropanes 10 decorated with (R)-phenylglycinol (R 3 = Ph, R 4 = H) and (R,R)-pseudoephedrine (R 3 = Me, R 4 = Ph) side chains. Highly stereoselective formation of bicyclic products 12 was observed in both cases, while diastereomers 13 were never detected.
Further exploration of this approach has met with synthetic challenges and was essentially unrewarded. Numerous experimentations proved that only 1-methyl-2-bromocyclopropane carboxylic acid is fairly suitable for the preparation of starting amides 10 (R 1 = Me). 14 In situ generation of cyclopropenyl amides 11 via 1,2-dehydrohalogenation using analogues of 10 with R 1 ≠ Me has severe limitations rendering this synthetic pathway impractical. Accordingly, we embarked on an alternative route to cyclopropenyl amides 11, via the Rh(II)-catalyzed [2 + 1] -cycloaddition of diazoacetates with trimethylsilylacetylene, 15 which was improved and tailored to our systems. 16 This approach was benchmarked on racemic cyclopropene amides derived from achiral amino alcohols. To this end, available 1-arylcycloprop-2-ene-1-carboxylic acids 15, 16 14 were derivatized with N-protected 2-aminoethanols and 3-aminopropanols 15 to afford the corresponding amides 16, which were used crude in the subsequent base-assisted cyclization (Scheme 3). We first probed the cyclization of amide 16aa, which reacted uneventfully affording oxazabicyclo [5.1.0 ]octanone 17aa as a sole product in good yield ( Figure 1 ). Note that 18-crown-6 ether was not used in this case, as compared to the earlier examples depicted in Scheme 1 and 2, 9-11 as this catalyst is required only in the 1,2-dehydrobromination step for efficient generation of cyclopropene. With the positive initial results in hand, we moved on to evaluate the effect of substituents at nitrogen (R 2 ) and sp 3-hybridized carbon of cyclopropene (R 1 ) on the cyclization propensity of cyclopropenylamides. We were pleased to see that N-methyl (17ab, 17bb, 17cb) and various N-benzyl 2-oxa-5-produce two products: (1S,4S,7S)-19 or (1R,4S,7R)-20 (mode I). Likewise, (R)-configuration at C-1 in the amino alcohol tether of 21 would give rise to diastereomers (1S, 3R,7S)-22 or (1R,3R,7R)-23, respectively (mode II). Two additional modes are possible when the diastereoselectivity is induced in the presence of two contiguous chiral centers at C-1 and C-2 of the amino alcohol tether. Thus, threo-(24) could potentially afford products (1S,3S,4S,7S)-25 or (1R,3S,4S,7R)-26 (mode III), while erythro-(27) could provide (1S,3R, 4S,7S)-28 and (1R,3R,4S,7R)-29, respectively (mode IV) (Scheme 4). The following discussion addresses all the above-mentioned cyclization modes in detail.
To probe mode I, a set of condensation reactions between 1-arylcycloprop-2-ene-1-carboxylic acids (14a−c) and chiral amino alcohols 30b−d were carried out, and thus obtained chiral cyclopropenes 18 were used crude in the cyclization (Scheme 5) under the standard reaction conditions described above (Scheme 3). We were very pleased to find that, in all cases, the enantiomerically pure (3S,6S,7S)-2-oxa-5-azabicyclo-[5.1.0]-octan-6-ones 19 were obtained as sole products (3R,6R,7R enantiomer was obtained for 19bc, originated from (R)-phenylglycinol). None of these reactions produced any detectable amounts of the diastereomers 20 ( Figure 2 ). The relative and absolute configuration of compound 19bd was unambiguously confirmed by single-crystal X-ray crystallography. 18 Our rationale for the origins of the high diastereoselectivity obtained in cyclization mode I is shown in Scheme 6. Our earlier computational studies performed on achiral models suggested that the transition state in 7-exo-trig cyclization (TS1) has a very rigid pseudoboat conformation, stabilized by a three-center coordinated potassium cation bound through the alkoxide and carbonyl oxygens as well as the anionic carbon atom. 9a Assuming the same transition state model is realized for the chiral substrates in the present studies, a nucleophilic attack at the now diastereotopic C-7 or C-8 would result in two nonequivalent reaction pathways a and b, respectively (Scheme 6). Path a, affording product 19, operates via a lower-energy transition state TS2a, in which substituent R 3 at C-4 assumes the thermodynamically more favored, pseudoequatorial (bowsprit) conformation. The alternative, higher-energy transition state TS2b, resulting from nucleophilic attack b, forces the R 3 group into a pseudoaxial (flagpole) position where it experiences a strong synpentane interaction with hydrogen at C-8, which disfavors formation of product 20.
To test mode II, (R)-2-(benzylamino)-1-phenylethan-1-ol (31) was condensed with cyclopropenylcarboxylic acid 14b, and the resulting amide 21b was subjected to the baseassisted cyclization. A 1:4 ratio of two isomeric products, 22b and 23b, was obtained (Scheme 7). Configurations of both products were unambiguously assigned by 2D NOESY experiments. 18 A mechanistic scenario consistent with the observed marginal diastereoselectivity is outlined in Scheme 8. It is believed that the unfavorable 1,3-diaxial interaction between substituent R 4 at C-5 and the R 2 group at nitrogen in the sevenmembered complex TS3a (resulting from path a) is not as prohibitive as in cyclohexyl analogues. As a result, 22 is produced as a minor product. An alternative, major pathway b proceeding via transition state TS3b, in which substituent R 4 at the stereogenic center is free of the unfavorable interactions, gives rise to major product 23 (Scheme 8).
Next, we tested modes III and IV on cyclopropenyl carboxamide derivatives prepared from cyclopropene carboxylic acids 14a−d and (+)-or (−)-pseudoephedrine (32 or ent-32) and (−)-ephedrine (33) . Cyclization of these substrates provided oxazepanones 25 (or ent-25) and 28, respectively, as sole products in excellent yields (Scheme 9, Figure 3 ). Single-crystal X-ray diffraction analysis unambiguously con-firmed the absolute configurations of products 25c and 28c. 18 The origins of high diastereoselectivity in the 7-exo-trig nucleophilic cyclization producing 25 (mode III) are analyzed in Scheme 10. It is believed that the nucleophilic attack at C-7 (path a) is highly preferred due to a more favored transition state TS4a, in which both substituents R 3 and R 4 occupy a pseudoequatorial position. A complementary path b would lead to a much more energetic transition state TS4b, in which substituent R 3 in a flagpole orientation is experiencing steric repulsions with hydrogen at C-8 (Scheme 10), similar to that described above for mode I (Scheme 6). The 1,3-diaxial interaction between substituents R 2 and R 4 could be another contributing factor to destabilization of TS4b. This effect, however, is not expected to be significant for small Nsubstituents, such as a methyl group.
Finally, the high selectivity observed in cyclization mode IV is rationalized as follows (Scheme 11). Transition state TS5a resulting from the nucleophilic attack at C-7 (path a) is rather favorable, since the 1,3-diaxial interaction between substituents R 2 and R 4 , as was stated above, is quite insignificant for nonbulky R 2 groups. The alternative transition state TS5b, resulting from an attack at C-8 (path b), experiences prohibitive steric interactions with a flagpole substituent R 3 (Scheme 11). Arguably, in all four cyclization modes analyzed above, the stereoselectivity is greatly influenced by configuration of the stereogenic center at C-4 and the R 3 group, while the C-5 substituent R 4 plays a modest role, at least for derivatives with a nonencumbered substituent on the nitrogen. The strong cation-templating effect elicits conformational rigidity of the transition state and amplifies the asymmetric induction arising from a rather remote chiral center, which ultimately allows for the efficient desymmetrization of the cyclopropenyl moiety.
The obtained enantiopure 2-oxa-5-azabicyclo[5.1.0]octan-6-ones constitute very attractive biological probes as this unique heterocyclic scaffold just recently emerged on the chemical space map. Accordingly, we performed a preliminary biological evaluation of a few representative compounds for antimicrobial and anticancer activities. The antiproliferative activity was assessed by using the cancer cell line, HeLa, as a model for human cervical adenocarcinoma, through the measurements of mitochondrial dehydrogenase activities using the MTT method. 19 In addition, the synthesized compounds were tested against Staphylococus epidermidis (ATCC 75984) and Escherichia coli (ATCC 25922), where minimum inhibitory concentrations (MICs) were determined by the broth micro-dilution method using MTT assay. 20 Since the described compounds bear some similarity with azepines known to possess activity against mycobacteria, 21 we also tested products 19, 25, and 28 against Mycobacterium abscessus (ATCC 19977) by MTT assay. The potency of synthesized compounds against yeasts was also evaluated using Candida albicans (ATCC 26555). significant cytotoxicity on HeLa cells. However, promising activity against Mycobacterium abscessus was observed for selected 2-oxa-5-azabicyclo[5.1.0]octan-6-ones ( Table 1) . The latter finding, coupled with apparent low general toxicity against cultured human cells, set the grounds for further SAR studies.
CONCLUSION
A potassium-templated, intramolecular nucleophilic addition of alkoxides to isolable, prochiral cyclopropenes has been developed. The scope of this cyclization and the mechanism of enantiomeric induction were investigated on a series of tethered chiral alkoxides. Three out of four tested chiral cyclization modes provided a highly efficient asymmetric induction, governed by the chiral center at C-4 and controlled by the strong chelating effect of potassium. The obtained optically active 2-oxa-5-azabicyclo[5.1.0]octan-6-ones were tested against representative mycobacterial infectioncausing organisms as well as other bacteria, pathogenic fungi, and human cultured cell lines. The biological profile exhibited by some of these unique chiral cyclopropane-fused mediumsized heterocycles is noteworthy and is currently being further explored in our laboratories.
EXPERIMENTAL SECTION

General.
NMR spectra were recorded on a Bruker Avance DRX-500 (500 MHz) with a dual carbon/ proton cryoprobe (CPDUL), Bruker III (400 MHz) equipped with BBO probe. 13 C NMR spectra were registered with broadband decoupling. The (+) and (−) designations represent positive and negative intensities of signals in 13 C DEPT-135 experiments. IR spectra were recorded on a ThermoFisher Nicolet iS 5 FT-IR spectrometer. HRMS was carried out on an LCT Premier (Micromass Technologies) instrument employing ESI TOF detection techniques. Glassware used in moisture-free syntheses was flame-dried in a vacuum prior to use. Column chromatography was carried out on silica gel (Sorbent Technologies, 40−63 mm). Precoated silica gel plates (Sorbent Technologies Silica XG 200 mm) were used for TLC analyses. Anhydrous dichloromethane was obtained by passing degassed commercially available HPLC-grade inhibitor-free solvent consecutively through two columns filled with activated alumina and stored over molecular sieves under nitrogen. Water was purified by dual-stage deionization followed by dual-stage reverse osmosis. Anhydrous THF was obtained by refluxing commercially available solvent over calcium hydride followed by distillation in a stream of dry nitrogen. 1-Phenylcycloprop-2-ene-1-carboxylic acid (14a), 22 1-(4-fluorophenyl)-cycloprop-2-ene-1-carboxylic acid (14b), 6d and (S)-2-(benzylamino)-4-methylpentan-1-ol (30d) 23 were synthesized according to the previously published procedures and had physical and spectral properties identical to those earlier reported. Syntheses of 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (14c), 1-(naphthalen-1-yl)cycloprop-2-ene-1-carboxylic acid (14d), and 2-((5-bromo-2-fluorobenzyl)amino)ethan-1-ol (15e) are described herein. 18 All other reagents and solvents were purchased from commercial vendors and used as received. See Supporting Information for the spectral charts and X-ray crystallography data. crystals and incubated further for 15 min. An amount of 50 μg/mL of colistin (PME) was used as a positive kill control for E. coli; 50 μg/mL of vancomycin was used as a positive kill control for S. epidermidis; and untreated cells served as negative controls. The experiments were performed in triplicate.
MTT Assay for Mycobacterium abscessus (ATCC 19977)
.-Approximately 5.5 × 10 5 mycobacteria per mL or a dilution of 1:500 from an overnight growth were plated at a final volume of 400 μL/well in 48-well plates. Compounds were initially screened at a concentration of 100 μM on M. abscessus. Compounds with antimycobacterial activity at 100 μM were screened for further activity by adding the selected compounds to cells at a concentration of 50 μM and 2-fold serially diluting. The plates were incubated in a shaking incubator for 48 h at 37 °C. Following the incubation, 40 μL or 10% w/v of MTT reagent (5 mg/mL) was added to each of the wells. The plates were incubated for 2 h at 37 °C. An amount of 650 μL of solubilization solution was added to each of the wells, and the plate was incubated at 37 °C for an additional 12 h. An amount of 100 μL from each well was transferred into a clear 96-well microtiter plate, and A595 was read in a Thermomax Molecular Device plate reader. Wells containing Middlebrook 7H9 medium and nontreated cells served as negative controls, and a well containing 10 μM PAO-treated cells served as a positive kill control. The experiments were performed in triplicate.
Synthesis of Starting Materials. (3.71 g, 11. 77 mmol, 1.00 equiv) in a mixture of methanol and THF (1:1, 100 mL) was stirred at 0 °C. A 1.5 M aqueous solution of NaOH (102 mL, 153.0 mmol, 13.0 equiv) was added dropwise, and the mixture was stirred for 18 h. Organic solvents were then removed under vacuum, and the remaining aqueous solution was washed with dichloromethane (3 × 50 mL). The remaining aqueous phase was acidified with 1 N aqueous HCl to pH 2 and extracted with dichloromethane (3 × 50 mL). The combined organic phases were washed with brine, dried with MgSO 4 , filtered, and concentrated. The product was isolated as a colorless solid (Rf 0.27, by column chromatography eluting with a hexane/ EtOAc mixture (2:1). Yield 2.10 g (9.16 mmol, 78%). 1 1-(Naphthalen-1-yl)cycloprop-2-ene-1-carboxylic acid (14d).-This compound was synthesized starting from 1-(naphthalen-1-yl)-2-(trimethylsilyl)cycloprop-2-ene-1-carboxylate 9b (3.82 g, 12. 9 mmol, 1.00 equiv) according to the procedure described above for preparation of acid 14c. The titled product was isolated by column chromatography eluting with a hexane/EtOAc mixture (2:1) as a colorless solid (R f 0.27, mp 144−145 °C). Yield 2.23 g (10.6 mmol, 82%). 1 
1-(2,4-Dichlorophenyl)-cycloprop-2-ene-1-carboxylic Acid (14c).-Solution
methyl 1-(2,4-dichlorophenyl)-2-(trimethylsilyl)cycloprop-2-ene-1-carboxylate 9b
2-((5-Bromo-2-fluorobenzyl)amino)ethan-1-ol (15e).-5-Bromo-2-
fluorobenzaldehyde (2 mL, 3.42 g, 16.8 mmol, 1.0 equiv), 2-aminoethan-1-ol (1.12 mL, 1.13 g, 18.5 mmol, 1.1 equiv), and 30 mL of anhydrous methanol were combined and stirred at RT overnight. The reaction mixture was cooled to 0 °C; NaBH 4 (955 mg, 25.3 mmol, 1.5 equiv) was added in portions; and the reaction mixture was stirred for 2 h at RT. The reaction mixture was concentrated in vacuum and partitioned between 10 mL of water and 10 mL of dichloromethane. The aqueous phase was then extracted with dichloromethane (2 × 10 mL). The combined organic phases were washed with brine (10 mL Cyclization of Achiral Substrates.
5-Benzyl-7-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one (17aa).-Typical
Procedure. A flame-dried round-bottom flask was charged with 1-phenylcycloprop-2-ene-1-carboxylic acid (14a) (500 mg, 3.12 mmol, 1.0 equiv), DMF (2 drops), and freshly distilled anhydrous dichloromethane (7 mL) under nitrogen atmosphere. Oxalyl chloride (400 μL, 592 mg, 4.68 mmol, 1.5 equiv) was then added dropwise, and the mixture was stirred at room temperature for 2 h. The solution was concentrated in a stream of nitrogen; the residue was subjected to a high vacuum, dissolved in anhydrous dichloromethane (2.0 mL), and added dropwise to a stirred solution of 2-(benzylamino)ethan-1-ol (15a) (708 mg, 4.68 mmol, 1.5 equiv) and triethylamine (1.3 mL, 948 mg, 9.36 mmol, 3.0 equiv) in anhydrous dichloromethane (3.0 mL). The reaction mixture was stirred at room temperature for 18 h and then partitioned between water (15 mL) and dichloromethane (20 mL) . The aqueous phase was acidified with 5 mL of 2 N HCl. The organic phase was then washed with 2 N HCl (3 × 10 mL). The combined aqueous layers were back-extracted once with 10 mL of dichloromethane, which was combined with other organic phases, washed with brine, dried with MgSO 4 , filtered, and concentrated. The product, N-benzyl-N-(2-hydroxyethyl)-1-phenylcycloprop-2-ene-1-carboxamide (16aa), was filtered through a silica plug using EtOAc and was used at the cyclization step as is without additional purification. An ovendried 1 mL Wheaton vial was charged with powdered KOH (7.6 mg, 0.136 mmol, 2.0 equiv) and anhydrous THF (400 μL). Crude amide 16aa (20 mg, 0.068 mmol) was added as a solution in anhydrous THF (400 μL). The mixture was vigorously stirred at 30 °C for 18 h, and then the reaction mixture was filtered through short plug of Silica gel eluting with EtOAc. The eluate was concentrated in vacuum. The product was isolated by column chromatography eluting with a hexane/EtOAc mixture (2:1) as a colorless oil (R f = 0.25). Yield 17.6 mg (0.060 mmol, 88% 5-Methyl-7-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one (17ab).-This compound was synthesized according to the typical procedure from 1-phenylcycloprop-2-ene-1-carboxylic acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and 2-(methylamino)ethan-1-ol (15b) (141 mg, 1.88 mmol, 1.5 equiv). After extraction and filtration through a silica plug, crude N-(2-hydroxyethyl)-N-methyl-1-phenylcycloprop-2-ene-1-carboxamide (16ab) was used at the cyclization step as is without additional purification. To this end, amide 16ab (20 mg, 0.092 mmol) was treated with powdered KOH (10.3 mg, 0.184 mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc mixture (1:1) = 15.6, 11.4, 6.3 Hz, 1H), 2H), 3.46 (dd, J = 6.2, 3.6 Hz, 1H), 1H), 1.74 (dd, J = 7.0, 3.6 Hz, 1H) hydroxyethyl)-N,1-diphenylcycloprop-2-ene-1-carboxamide (16af) was isolated and used at the cyclization step without additional purification. To this end, amide 16af (20 mg, 0.072 mmol) was treated with powdered KOH (8 mg, 0.144 mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc mixture (1:1) as a colorless glass (R f = 0.48). Yield 5.8 mg (0.021 mmol, 29%). 1 H NMR (500 MHz, CDCl 3 ): δ 7. 2H), 4H), 2H), 2H), 4.37 (ddd, J = 15.4, 12.6, 4.9 Hz, 1H), 3.94 (ddd, J = 12.5, 11.5, 4.8 Hz, 1H), 3.76 (dd, J = 11.4, 4.9 Hz, 1H), 3.54 (dd, J = 6.3, 3.6 Hz, 1H), 3.47 (dd, J = 15.4, 4.7 Hz, 1H) 
6-Benzyl-8-phenyl-2-oxa-6-azabicyclo[6.1.0]nonan-7-one (17ah).-This
compound was synthesized according to the typical procedure from 1-phenylcycloprop-2-ene-1-carboxylic acid (14a) (200 mg, 1.25 mmol, 1.0 equiv) and 3-(benzylamino)propan-1-ol (15h) (309 mg, 1.88 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude N-benzyl-N-(3-hydroxypropyl)-1-phenylcycloprop-2-ene-1-carboxamide (16ah) was used at the cyclization step as is without additional purification. To this end, amide 16ah (20 mg, 0.065 mmol) was treated with powdered KOH (7.3 mg, 0.13 mmol). The product was isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless solid (R f = 0.31, mp 148−150 °C). Yield 18 mg (0.059 mmol, 90%). 1 
5-Benzyl-7-(4-fluorophenyl)-2-oxa-5-azabicyclo[5.1.0]octan-6-one (17ba).-This
compound was synthesized according to the typical procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-carboxylic acid (14b) (200 mg, 1.12 mmol, 1.0 equiv) and 2-(benzylamino)ethan-1-ol (15a) (255 mg, 1.68 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude N-benzyl-1-(4-fluorophenyl)-N-(2-hydroxyethyl)cycloprop-2-ene-1-carboxamide (16ba) was used at the cyclization step as is without additional purification. To this end, amide 16ba (20 mg, 0.064 mmol) was treated with powdered KOH (7.2 mg, 0.128 mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc mixture (1:1) as a colorless glass (R f =0.44). Yield 18 mg (0.058 mmol, 90%). 1 
7-(4-Fluorophenyl)-5-(4-methoxyphenyl)-2-oxa-5-azabicyclo-[5.1.0]octan-6-one (17bg)
.-This compound was synthesized according to the typical procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-carboxylic acid (14b) (200 mg, 1.12 mmol, 1.0 equiv) and 2-((4-methoxyphenyl)amino)ethan-1-ol (15g) (282 mg, 1.68 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude 1-(4-fluorophenyl)-N-(2-hydroxyethyl)-N-(4-methoxyphenyl)cycloprop-2-ene (16bg) was used at the cyclization step as is without additional purification. To this end, amide 16bg (20 mg, 0.061 mmol) was treated with powdered KOH (6.9 mg, 0.122 mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc mixture (2:1) as a colorless solid (R f 0.19, mp 132−133 °C). Yield 18.4 mg (0.056 mmol, 92%). 1 H NMR (500 MHz, CDCl 3 ): δ 7. 2H), 2H), 2H), 2H), 4.32 (ddd, J = 15.4, 12.6, 4.9 Hz, 1H), 3.91 (td, J = 11.9, 4.7 Hz, 1H), 3.81 (s, 3H), 3.74 (dd, J = 11.0, 5.1 Hz, 1H), 3.50 (dd, J = 6.2, 3.5 Hz, 1H), 3.38 (dt, J = 19.4, 9.7 Hz, 1H) (16bi) was used at the cyclization step as is without additional purification. To this end, amide 16bi (20 mg, 0.056 mmol) was treated with powdered KOH (6.2 mg, 0.112 mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc mixture (2:1) as a colorless glass (R f = 0.19). Yield 18.4 mg (0.051 mmol, 92%). 1 H NMR (500 MHz, CDCl 3 ): δ 7.38 1H), 1H), 2H), 2H), 2H), 5.29 (d, J = 15.4 Hz, 1H), 4.36 (d, J = 15.4 Hz, 1H), 4.24 (dd, J = 12.8, 5.6 Hz, 1H), 3.94 (dd, J = 15.6, 11.2 Hz, 1H), 3.90 (dd, J = 7.5, 4.4 Hz, 1H), 3.75 (tt, J = 14.4, 7.2 Hz, 1H), 3.15 (dd, J = 15.5, 6.6 Hz, 1H), 1H), 1.82 (dd, J = 7.0, 4.4 Hz, 1H), 1.58 (ddd, J = 15.1, 6.5, 3.1 Hz, 1H) -7-(2,4-dichlorophenyl)-2-oxa-5-azabicyclo[5.1.0]octan-6-one (17ca) .-This compound was synthesized according to the typical procedure from 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (14c) (200 mg, 0.87 mmol, 1.0 equiv) and 2-(benzylamino)ethan-1-ol (15a) (198 mg, 1.31 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude N-benzyl-1-(2,4-dichlorophenyl)-N-(2-hydroxyethyl)cycloprop-2-ene-1-carboxamide (16ca) was used at the cyclization step as is without additional purification. To this end, amide 16ca (20 mg, 0.055 mmol) was treated with powdered KOH (6.2 mg, 0.11 mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc mixture (2:1) -This compound was synthesized according to the typical procedure from 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (14c) (200 mg, 0.87 mmol, 1.0 equiv) and 2-(methylamino)ethan-1-ol (15b) (98 mg, 1.31 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude 1-(2,4-dichlorophenyl)-N-(2-hydroxyethyl)-Nmethylcycloprop-2-ene-1-carboxamide (16cb) was used at the cyclization step as is without additional purification. To this end, amide 16cb (20 mg, 0.07 mmol) was treated with powdered KOH (7.8 mg, 0.14 mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc mixture (1:2) 1, 22.3 (−) . FTIR (NaCl, cm −1 ): 1647, 1474, 1253, 1169 . HRMS (TOF ES): found 308.0210, calculated for C 13 H 13 Cl 2 NO 2 Na (M + Na) 308.0221 (3.6 ppm). -8-(2,4-dichlorophenyl)-2-oxa-6-azabicyclo[6.1.0]-nonan-7-one (17ch) . -This compound was synthesized according to the typical procedure from 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (14c) (200 mg, 0.87 mmol, 1.0 equiv) and 3-(benzylamino)propan-1-ol (15h) (216 mg, 1.31 mmol, 1.5 equiv). After extraction and filtration through a silica plug crude N-benzyl-1-(2,4-dichlorophenyl)-N-(3-hydroxypropyl)cycloprop-2-ene-1-carboxamide (16ch) was used at the cyclization step as is without additional purification. To this end, amide 16ch (20 mg, 0.053 mmol) was treated with powdered KOH (6 mg, 0.106 mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc mixture (1:1) 11H), 2H), 2H), 5.44 (d, J = 15.8 Hz, 1H), 4.76 (dddd, J = 11.7, 9.1, 6.1, 4.5 Hz, 1H), 4.06 (d, J = 15.7 Hz, 1H), 3.50 (dd, J = 6.3, 3.6 Hz, 1H), 3.44 (dd, J = 11.1, 4.5 Hz, 1H), 3.07 (t, J = 11.4 Hz, 1H) 7.22 (m, 3H), 6H), 1H), 2H), 3.39 (dd, J = 6.3, 3.5 Hz, 1H), 1H), 2.92 (s, 3H), 2.80 (dd, J = 14.9, 5.8 Hz, 1H), 1.69 (dd, J = 7.2, 3.5 Hz, 1H), 1.45 (dd, J = 7.2, 6.3 Hz, 1H) . 13 C{ 1 H} NMR (126 MHz, CDCl 3 ): δ 171. 5, 161.9 (d, J = 245.6 Hz), 136.7, 133.4 (d, J = 3.1 Hz), 128.8 (+, 2C), 128.5 (+, 2C) , 127.1 (+), 126.4 (d, J = 7.9 Hz, +, 2C), 115.7 (d, J = 21.4 Hz, +, 2C), 59.5 (+) , 55.1 (+), 34.6, 34.1 (−), 27.3 (+), 23.0 (−) . . After extraction and filtration through a silica plug crude (S)-1-(2,4-dichlorophenyl)-N-(1-hydroxy-3-phenylpropan-2-yl)-N-methylcycloprop-2-ene-1-carboxamide (18ca) was used at the cyclization step as is without additional purification. To this end, amide 18ca (20 mg, 0.053 mmol) was treated with powdered KOH (5.9 mg, 0.106 mmol). The product was isolated by column chromatography eluting with a hexane/EtOAc mixture (1:1) as a colorless oil (R f = 0.5). Yield 16.8 mg (0.045 mmol, 84% Structures and yields of racemic cyclization products 17. Yields of purified materials are provided.
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